2023-507720-23-00CompletedPhase 1/2
A Study to assess the safety and potential use of GEH121224 (18F) Injection to visualise HER2-Receptor expression using PET imaging in patients with Metastatic Breast Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Jun 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 15 Nov 2024
- Lead sponsor
- GE Healthcare Limited
- Diseases
- Metastatic breast cancer
- EU CT number
- 2023-507720-23-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 43
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska University Hospital | Huddinge | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.